Tirzepatide is the f irst-in-class dual agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors bringing a novel, synergistic approach to glycaemic and weight control. This dual mechanism enhances insulin secretion in a glucose-dependent manner, suppresses glucagon, and slows gastric emptying while also influencing appetite regulation, leading to significant weight reduction.
Beyond glycaemic control, emerging evidence highlights its broader metabolic impact, including: Improvements in lipid metabolism Potential benefits in the cardiorenal system Promising effects in conditions like MASH and HFpEF By addressing multiple metabolic pathways simultaneously, tirzepatide represents a paradigm shift in the management of type 2 diabetes and obesity . Watch the video to explore how the dual incretin action of tirzepatide is…
